AbbVie’s immunology duo Skyrizi and Rinvoq is, in a rare blip this year, not leading the pharma DTC monthly rankings as ...

"Boehringer-Ingelheim sees China as a focus market and a source of innovation. We have firmly believed that this market is of ...

"In my opinion, the CIIE not only reflects China's economic and trade dynamic, but also the country's determination to ...

近日，邓迪大学（University of Dundee）和勃林格殷格翰（Boehringer Ingelheim）公司的科学家合作，开发了一种能够降解多种KRAS突变体的广谱靶向蛋白降解疗法，为治疗多种难治性癌症提供了新选择。这项研究已经发表在顶尖科学期刊《科学》上。

Onsite at the Boehringer Ingelheim R&D centre in Biberach, Germany, the conversation also circled around Boehringer’s One Medicine Project, originally announced in March 2022, but the central focus ...

The solution combines three medications delivering the broadest spectrum of protection against internal and external ...

German pharma giant claims Granules India’s ANDA infringes five patents I Combination therapy Jentadueto among Boehringer’s ...

New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara BioCapital and SV Health Investors Enara Bio’s EDAPT® ...

The approach can be transformative. When patients feel heard and understood, they’re more likely to engage actively and ...

Home-based phototherapy for plaque and guttate psoriasis is as effective as office-based phototherapy, results of the ...

Generative AI should be able to write usable doctor's letters and thus potentially speed up medical documentation, according ...

New investors Pfizer Ventures and M Ventures co-led the financing, with participation from all existing investors including RA Capital, Samsara ...